Literature DB >> 9482880

BRCA1 regulates p53-dependent gene expression.

T Ouchi1, A N Monteiro, A August, S A Aaronson, H Hanafusa.   

Abstract

Mutations in BRCA1 are present in 45% of families that segregate with susceptibility for breast cancer and in 80-90% of families with both breast and ovarian cancer. Here we report that BRCA1 stimulates artificial and genomic promoter constructs containing p53-responsive elements. This activity of BRCA1 depends on the presence of wild-type p53, which was shown by using mouse fibroblasts expressing temperature-sensitive forms of p53, or p53(+/+) and p53(-/-) fibroblasts obtained from p53 knockout mice. Furthermore, mutant forms of BRCA1 lacking the C-terminal second BRCA1 C-terminal (BRCT) domain showed reduced p53-mediated transcriptional activation. Finally, we found that BRCA1 coimmunoprecipitates with p53, in vitro and in vivo. These findings suggest a function of BRCA1 as a p53 coactivator.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482880      PMCID: PMC19327          DOI: 10.1073/pnas.95.5.2302

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  p53: puzzle and paradigm.

Authors:  L J Ko; C Prives
Journal:  Genes Dev       Date:  1996-05-01       Impact factor: 11.361

2.  Small peptides activate the latent sequence-specific DNA binding function of p53.

Authors:  T R Hupp; A Sparks; D P Lane
Journal:  Cell       Date:  1995-10-20       Impact factor: 41.582

3.  Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus.

Authors:  J Jayaraman; C Prives
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

4.  Location of BRCA1 in human breast and ovarian cancer cells.

Authors:  R Scully; S Ganesan; M Brown; J A De Caprio; S A Cannistra; J Feunteun; S Schnitt; D M Livingston
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

Review 5.  Post-translational modification of p53.

Authors:  D W Meek
Journal:  Semin Cancer Biol       Date:  1994-06       Impact factor: 15.707

6.  Growth retardation and tumour inhibition by BRCA1.

Authors:  J T Holt; M E Thompson; C Szabo; C Robinson-Benion; C L Arteaga; M C King; R A Jensen
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

7.  Allosteric activation of latent p53 tetramers.

Authors:  T R Hupp; D P Lane
Journal:  Curr Biol       Date:  1994-10-01       Impact factor: 10.834

8.  p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction.

Authors:  H W Stürzbecher; B Donzelmann; W Henning; U Knippschild; S Buchhop
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

9.  Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.

Authors:  S A Gayther; W Warren; S Mazoyer; P A Russell; P A Harrington; M Chiano; S Seal; R Hamoudi; E J van Rensburg; A M Dunning; R Love; G Evans; D Easton; D Clayton; M R Stratton; B A Ponder
Journal:  Nat Genet       Date:  1995-12       Impact factor: 38.330

10.  Aberrant subcellular localization of BRCA1 in breast cancer.

Authors:  Y Chen; C F Chen; D J Riley; D C Allred; P L Chen; D Von Hoff; C K Osborne; W H Lee
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  86 in total

1.  BRCA1 can stimulate gene transcription by a unique mechanism.

Authors:  G Nadeau; N Boufaied; A Moisan; K M Lemieux; C Cayanan; A N Monteiro; L Gaudreau
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

Review 2.  Molecular interaction map of the mammalian cell cycle control and DNA repair systems.

Authors:  K W Kohn
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

3.  BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.

Authors:  H Ruffner; W Jiang; A G Craig; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 4.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 5.  Functional domains of the BRCA1 and BRCA2 proteins.

Authors:  R Baer; W H Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-10       Impact factor: 2.673

6.  BRCA1 interacts with components of the histone deacetylase complex.

Authors:  R I Yarden; L C Brody
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 7.  Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease.

Authors:  F J Oliver; J Menissier-de Murcia; G de Murcia
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

8.  BRCA1 at a branch point.

Authors:  J D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

9.  BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets.

Authors:  Timothy K MacLachlan; Rishu Takimoto; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

10.  BRCA1 partially reverses the transforming activity of the ras oncogene.

Authors:  A Kumar; C Knott; K Kuus-Reichel; M S Saedi
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.